IPTACOPAN ASH UPDATE
Iptacopan monotherapy was superior to SoC at reducing patient-
reported fatigue from baseline
Mean FACIT-Fatigue score (SD) during the 24-week randomized treatment period
50
45-
40-
35
Mean FACIT-Fatigue score (SD)
25
88
30
25
20-
Wk18
Wk20
Wk22
Wk24
15.
BL Wk1 WK2
Wk6
Patients with available data
Iptacopan 62 60 57
Anti-C5 SoC 33 27 28
61
32
Wk12
Study visit
57
29
58
59
56
60
29
28
28
30
Adjusted mean change from baseline¹ in FACIT-Fatigue score (95% CI) was +8.59 (6.72, 10.47) for iptacopan vs +0.31 (-2.20, 2.81) for SoC, with a difference of +8.29 (5.28, 11.29) (P<0.00012)
1. Between Days 126 and 168. 2. A repeated measures model, adjusting for covariates including baseline FACIT-Fatigue score, was used for comparisons between the treatment arms. P value is two-sided and unadjusted.
14
IPTACOPAN ASH UPDATE | DECEMBER 13, 2022
NOVARTIS | Reimagining MedicineView entire presentation